Minaris Regenerative Medicine, LLC news

Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership.

Hiroto Bando, PhD, who joined Minaris Regenerative Medicine as Deputy General Manager, Regenerative Medicine Business Sector (RMBS), Showa Denko Materials Co., Ltd., in November 2020, will become General Manager, RMBS as well as President and Chief Executive Officer of Minaris Regenerative Medicine, LLC in the United States, effective J

Minaris Regenerative Medicine (United States) welcomes Emmanuelle Bommier in the role of Senior Director, Business Development, effective August 30, 2021.

In her role as head of business development for North America, reporting to CEO, Dr. Kazuchika Furuishi, Emmanuelle will be accountable for creating new business opportunities and client management for Minaris in the United States, as well as for global new business opportunities, with indirect reporting to Luc St-Onge, Global Head

Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for Skysona^TM (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. Today, the European Commission (EC) has granted marketing authorization for Skysona^TM, the first and only gene therapy for patients with Ear

Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership.

Minaris Regenerative Medicine, having facilities in the U.S., Germany, and Japan, will shift to a model of regional operational leadership on October 1, 2021. Under the new model, its three regional Chief Operating Officers (COOs) will collaborate on a Global Functional team to ensure alignment across the three regional companies. This shift is expected to allow for